Navigation Links
DNA2.0 Patents New DNA Cloning Method
Date:12/14/2012

Menlo Park, CA (PRWEB) December 13, 2012

DNA2.0, the leading bioengineering solutions provider, today announced that it has been awarded US patent 8,323,930 for a new cloning method that facilitates high-throughput manufacturing of synthetic DNA. The company’s new technology for one-step DNA cloning is based on the DNA topoisomerase enzyme and its capacity to nick and reanneal DNA. Because the process does not rely on PCR, DNA2.0’s method ensures no introduced sequence errors in the cloned version of the newly manufactured synthetic gene.

“Industrializing the production of synthetic genes requires more than simply increasing the capacity and accuracy of oligonucleotide synthesis. Accordingly, DNA2.0 has developed a new method to efficiently and consistently clone assembled oligonucleotides to generate clonal entities in a one-step process,” said Jeremy Minshull, CEO and cofounder of DNA2.0. “DNA2.0 is proud to be an innovation leader so that our customers can focus on their research rather than reinventing the wheel. We are excited to add this patent to our growing portfolio of technological achievements in synthetic biology.”

About DNA2.0
DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 offers an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis, and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly effici
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. DNA2.0 Patents Key Method for Synthesizing Bioplastic Polymer
2. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
3. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
4. ERT Granted Patents on Clinical Trial Participant Compliance
5. Olympus Licenses Digital Pathology Patents to Zeiss
6. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
7. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
8. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
9. Cloning could make structurally pure nanotubes for nanoelectronics
10. Rigaku Publishes New Application Note: Cement Raw Meal Analysis by Pressed Powder Method on the ZSX Primus III+
11. Sequenom, Inc. Announces Issuance Of Patent For Methods Of Detecting Fetal Aneuploidy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... With a larger, brighter interface, ... Cole-Parmer® Digital Gear Pump Drive for Micropump® ... for automated process applications. , Simply set time ... count function counts down and displays batches completed ... dispensed across multiple cycles. View the four operating ...
(Date:7/21/2014)... (July 21, 2014) The yield so far ... have developed a low-energy, solution-based mineral substitution process to ... find use in electronics and alternative energy devices. , ... cover of the July 21 issue of the journal ... of research in the inorganic and nuclear chemistry fields. ...
(Date:7/21/2014)... Sleep disturbances such as insomnia, hypersomnia, ... depression. According to a study published by the ... of depressed patients have insomnia symptoms, and hypersomnia ... adults and 10% of older patients, with a ... have a major impact on quality of life, ...
(Date:7/19/2014)... 20, 2014 United States Non-Vascular ... GlobalDatas new report, "United States Non-Vascular Stents Market ... the United States Non-Vascular Stents market. The report ... (in units) and average prices (in US dollars) ... Stents and Metal Biliary Stents (Metal Non-Covered Biliary ...
Breaking Biology Technology:New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2Oregon chemists eye improved thin films with metal substitution 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 2United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 4
... Pharmaceuticals, Inc. (NYSE Amex: ANX ) today ... ended December 31, 2008."2008 was a transition year for ... focused on lower-risk reformulations of previously-approved drugs. We achieved ... the difficult economic environment, we were unable to attract ...
... Insmed Inc. (Nasdaq: INSM ), a developer of ... March 23, 2009, NASDAQ issued a notice further extending the ... price and those rules requiring a minimum market value of ... effect through Friday, July 17, 2009, and the original rules ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... patient enrolment in its U.K. clinical trial to ... REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients ... neck. The principal investigators are Dr. Johann de ...
Cached Biology Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 7Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
(Date:7/22/2014)... -- Stem cells offer much promise for treating damaged ... cell survival is poor, limiting their effectiveness. New methods ... and optimize their therapeutic function after transplantation, as described ... , a peer-reviewed journal from Mary Ann Liebert, Inc., ... BioResearch Open Access website . , ...
(Date:7/22/2014)... research has shown squirrels have adapted to New York ... well, if not better, than their fellow squirrels in ... Curtin,s Department of Environment & Agriculture, led the study ... their behaviour in urban environments and prevent unnecessary responses ... staying on the footpath. , "As we rapidly ...
(Date:7/22/2014)... of meerkats which sees them prevent their daughters from ... new study. , Research into the desert creatures which ... adult helpers shows that the alpha female can flourish ... study shows how this way of life, also found in ... despite its sinister side. , Dominant meerkats control breeding ...
Breaking Biology News(10 mins):New York squirrels are nuts about city life 2
... novel,vaccine that uses immune cells as factories to produce ... breast cancers, say researchers at,The University of Texas M. ... is a protein often present / surexpressed in ... Breast Cancer Research,on Nov. 29, 2004, showed that the ...
... NGEN), developer of advanced diagnostic products, announced today that ... Biologic Array" by the U.S. Patent and Trademark Office. ... one or more electrodes (or "test sites") across multiple ... covers a method for storing the value of the ...
... the Dana-Farber Cancer Institute report a surprising finding about ... only in the embryo itself, but also in the ... , Meticulous experiments in mice revealed that the placenta ... These cells, which appear very early in development, are ...
Cached Biology News:Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 2Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 3Nanogen Issued Patent for Electronic Microarray With Memory 2Placenta Is A Rich Source Of Blood Stem Cells 2
... anti-phospho-IRS1 (Tyr896) ... amino acid region encompassing the ... (Tyr896). Accession ... Quality Assurance: Routinely ...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
CCNI Antibody...
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
Biology Products: